In a randomized 1:1:1 Phase III study in ovarian cancer patients comparing (1) cediranib-plus-olaparib, (2) olaparib, and (3) platinum chemotherapy (the standard of care), the treatment with cediranib-plus-olaparib showed similar clinical activity to platinum in the BRCA1/2-mutation-positive group (Liu et al, 2022). Here, BRCA1 is linked to ovarian carcinoma.